Company intelligence / Profile preview

Accrofab

Ownership: Private
Development stage: Commercial

Overview

Accro Bioscience (aka Accropeutics) is a clinical-stage biotechnology company focused on developing novel small molecules targeting regulated cell death mechanisms for immune-mediated inflammatory diseases. They have multiple programs in their pipeline, with AC-201 recently showing positive Phase II results for moderate-to-severe plaque psoriasis, and AC-101 progressing through Phase Ib in China with planned multi-regional Phase II trials for Ulcerative Colitis. AC-003 is in Phase I for Acute Graft Versus Host Disease.

Therapeutic areas: GastroenterologyDermatologyOphthalmologyImmunology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Accrofab.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Accrofab.

Explore the full profile